15. november 2007

Tähelepanu! Artikkel on enam kui 5 aastat vana ning kuulub väljaande digitaalsesse arhiivi. Väljaanne ei uuenda ega kaasajasta arhiveeritud sisu, mistõttu võib olla vajalik kaasaegsete allikatega tutvumine.

<em><br /></em>NEW YORK amp; WELLESLEY- Mass.--(BUSINESSWIRE)--Nov. 16- 2007--Pfizer Inc (NYSE: PFE) announced today it hasentered into an agreement to acquire Coley Pharmaceutical Group-Inc. (NASDAQ: COLY)- a publicly-held biopharmaceutical companyspecializing in vaccine adjuvant technology and a new class ofimmunomodulatory drug candidates designed to fight cancers- allergyand asthma disorders- and autoimmune diseases.

Under the terms of the agreement- Pfizer will make a cash tenderoffer for all of the outstanding common stock of Coley for $8.00per share- representing an enterprise value of $164 million. Thetransaction is subject to customary closing conditions- includingapproval under the Hart-Scott-Rodino Antitrust Improvements Act of1976 and the acquisition by Pfizer of a majority of Coley's shares.Shareholders holding approximately 27% of the Coley shares haveentered into agreements to tender their shares in the offer.